ORIGINAL ARTICLE

Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma

S A Kharitonov, L E Donnelly, P Montuschi, M Corradi, J V Collins, P J Barnes

Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, Royal Brompton & Harefield NHS Trust, London SW3 6LY, UK

Correspondence to:
Correspondence to:
Professor P J Barnes, Department of Thoracic Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY;
p.j.barnes{at}ic.ac.uk

Background: Dose dependent anti-inflammatory effects of inhaled corticosteroids in asthma are difficult to demonstrate in clinical practice. The anti-inflammatory effect of low dose inhaled budesonide on non-invasive exhaled markers of inflammation and oxidative stress were assessed in patients with mild asthma.

Methods: 28 patients entered a double blind, placebo controlled, parallel group study and were randomly given either 100 or 400 µg budesonide or placebo once daily, inhaled from a dry powder inhaler (Turbohaler), for 3 weeks followed by 1 week without treatment. Exhaled nitric oxide (NO), exhaled carbon monoxide (CO), nitrite/nitrate, S-nitrosothiols, and 8-isoprostanes in exhaled breath condensate were measured four times during weeks 1 and 4, and once a week during weeks 2 and 3.

Results: A dose-dependent speed of onset and cessation of action of budesonide was seen on exhaled NO and asthma symptoms. Treatment with 400 µg/day reduced exhaled NO faster (–2.06 (0.37) ppb/day) than 100 µg/day (–0.51 (0.35) ppb/day; p<0.01). The mean difference between the effect of 100 and 400 µg budesonide was –1.55 ppb/day (95% CI –2.50 to –0.60). Pretreatment NO levels were positively related to the subsequent speed of reduction during the first 3–5 days of treatment. Faster recovery of exhaled NO was seen after stopping treatment with budesonide 400 µg/day (1.89 (1.43) ppb/day) than 100 µg/day (0.49 (0.34) ppb/day, p<0.01). The mean difference between the effect of 100 and 400 µg budesonide was 1.40 ppb/day (95% CI –0.49 to 2.31). Symptom improvement was dose-dependent, although symptoms returned faster in patients treated with 400 µg/day. A significant reduction in exhaled nitrite/nitrate and S-nitrosothiols after budesonide treatment was not dose-dependent. There were no significant changes in exhaled CO or 8-isoprostanes in breath condensate.

Conclusion: Measurement of exhaled NO levels can indicate a dose-dependent onset and cessation of anti-inflammatory action of inhaled corticosteroids in patients with mild asthma.

Keywords: exhaled nitric oxide; asthma; budesonide

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Sood, A., Qualls, C., Arynchyn, A., Beckett, W. S., Gross, M. D., Steffes, M. W., Smith, L. J., Holvoet, P., Thyagarajan, B., Jacobs, D. R. Jr (2009). Obesity-Asthma Association: Is It Explained by Systemic Oxidant Stress?. Chest 136: 1055-1062 [Abstract] [Full Text]  
• Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., de Jongste, J. C., Kerstjens, H. A. M., Lazarus, S. C., Levy, M. L., O'Byrne, P. M., Partridge, M. R., Pavord, I. D., Sears, M. R., Sterk, P. J., Stoloff, S. W., Sullivan, S. D., Szefler, S. J., Thomas, M. D., Wenzel, S. E., on behalf of the American Thoracic Society/Europea, (2009). An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice. Am. J. Respir. Crit. Care Med. 180: 59-99 [Abstract] [Full Text]  
• Brindicci, C., Ito, K., Torre, O., Barnes, P. J., Kharitonov, S. A. (2009). Effects of Aminoguanidine, an Inhibitor of Inducible Nitric Oxide Synthase, on Nitric Oxide Production and Its Metabolites in Healthy Control Subjects, Healthy Smokers, and COPD Patients. Chest 135: 353-367 [Abstract] [Full Text]  
• Oh, M.-J., Lee, J.-Y., Lee, B.-J., Choi, D.-C. (2008). Exhaled Nitric Oxide Measurement Is Useful for the Exclusion of Nonasthmatic Eosinophilic Bronchitis in Patients With Chronic Cough. Chest 134: 990-995 [Abstract] [Full Text]  
• Borrill, Z. L., Roy, K., Singh, D. (2008). Exhaled breath condensate biomarkers in COPD. Eur Respir J 32: 472-486 [Abstract] [Full Text]  
• van Veen, I. H., ten Brinke, A., Sterk, P. J., Sont, J. K., Gauw, S. A., Rabe, K. F., Bel, E. H. (2008). Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 32: 344-349 [Abstract] [Full Text]  
• Lim, K. G., Mottram, C. (2008). The Use of Fraction of Exhaled Nitric Oxide in Pulmonary Practice. Chest 133: 1232-1242 [Abstract] [Full Text]  
• Hahn, P. Y., Morgenthaler, T. I., Lim, K. G. (2007). Use of Exhaled Nitric Oxide in Predicting Response to Inhaled Corticosteroids for Chronic Cough. Mayo Clin Proc. 82: 1350-1355 [Abstract] [Full Text]  
• Montuschi, P. (2007). Review: Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications. Ther Adv Respir Dis 1: 5-23 [Abstract]  
• Travers, J., Marsh, S., Aldington, S., Williams, M., Shirtcliffe, P., Pritchard, A., Weatherall, M., Beasley, R. (2007). Reference Ranges for Exhaled Nitric Oxide Derived from a Random Community Survey of Adults. Am. J. Respir. Crit. Care Med. 176: 238-242 [Abstract] [Full Text]  
• Roy, K., Borrill, Z. L., Starkey, C., Hazel, A. L., Morris, J., Vestbo, J., Singh, D. (2007). Use of different exhaled nitric oxide multiple flow rate models in COPD. Eur Respir J 29: 651-659 [Abstract] [Full Text]  
• Paredi, P., Ward, S., Cramer, D., Barnes, P. J., Kharitonov, S. A. (2007). Normal Bronchial Blood Flow in COPD Is Unaffected by Inhaled Corticosteroids and Correlates With Exhaled Nitric Oxide. Chest 131: 1075-1081 [Abstract] [Full Text]  
• Barnes, P. J. (2007). Scientific rationale for using a single inhaler for asthma control. Eur Respir J 29: 587-595 [Abstract] [Full Text]  
• Batra, J., Pratap Singh, T., Mabalirajan, U., Sinha, A., Prasad, R., Ghosh, B. (2007). Association of inducible nitric oxide synthase with asthma severity, total serum immunoglobulin E and blood eosinophil levels. Thorax 62: 16-22 [Abstract] [Full Text]  
• Kharitonov, S. A., Barnes, P. J. (2006). Exhaled biomarkers.. Chest 130: 1541-1546 [Abstract] [Full Text]  
• Haahtela, T., Tamminen, K., Malmberg, L. P., Zetterstrom, O., Karjalainen, J., Yla-Outinen, H., Svahn, T., Ekstrom, T., Selroos, O. (2006). Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study. Eur Respir J 28: 748-755 [Abstract] [Full Text]  
• Taylor, D R, Pijnenburg, M W, Smith, A D, Jongste, J C D (2006). Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 61: 817-827 [Abstract] [Full Text]  
• Choi, J., Hoffman, L. A., Rodway, G. W., Sethi, J. M. (2006). Markers of lung disease in exhaled breath: nitric oxide.. Biol Res Nurs 7: 241-255 [Abstract]  
• Horvath, I., Hunt, J., Barnes, P. J., On behalf of the ATS/ERS Task Force on Exhaled Bre, (2005). Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 26: 523-548 [Abstract] [Full Text]  
• Overbeek, S. E., Mulder, P. G., Baelemans, S. M., Hoogsteden, H. C., Prins, J.-B. (2005). Formoterol Added to Low-Dose Budesonide Has No Additional Antiinflammatory Effect in Asthmatic Patients. Chest 128: 1121-1127 [Abstract] [Full Text]  
• Smith, A. D., Cowan, J. O., Brassett, K. P., Filsell, S., McLachlan, C., Monti-Sheehan, G., Herbison, G. P., Taylor, D. R. (2005). Exhaled Nitric Oxide: A Predictor of Steroid Response. Am. J. Respir. Crit. Care Med. 172: 453-459 [Abstract] [Full Text]  
• Battaglia, S, den Hertog, H, Timmers, M C, Lazeroms, S P G, Vignola, A M, Rabe, K F, Bellia, V, Hiemstra, P S, Sterk, P J (2005). Small airways function and molecular markers in exhaled air in mild asthma. Thorax 60: 639-644 [Abstract] [Full Text]  
• Smith, A. D., Cowan, J. O., Brassett, K. P., Herbison, G. P., Taylor, D. R. (2005). Use of Exhaled Nitric Oxide Measurements to Guide Treatment in Chronic Asthma. NEJM 352: 2163-2173 [Abstract] [Full Text]  
• Baydur, A. (2005). Not All That Comes Out Is Hot Air. Chest 127: 1482-1485 [Full Text]  
• Horvath, I (2005). The exhaled biomarker puzzle: bacteria play their card in the exhaled nitric oxide-exhaled breath condensate nitrite game. Thorax 60: 179-180 [Full Text]  
• Carpagnano, G E, Kharitonov, S A, Foschino-Barbaro, M P, Resta, O, Gramiccioni, E, Barnes, P J (2004). Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax 59: 1016-1019 [Abstract] [Full Text]  
• Kharitonov, S. A., Barnes, P. J. (2004). Effects of Corticosteroids on Noninvasive Biomarkers of Inflammation in Asthma and Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 1: 191-199 [Abstract] [Full Text]  
• Kharitonov, S.A., Gonio, F., Kelly, C., Meah, S., Barnes, P.J. (2003). Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J 21: 433-438 [Abstract] [Full Text]